Dose modification in enzalutamide and abiraterone plus prednisolone for castration‐resistant prostate cancer: A subanalysis from the ENABLE study for PCa
The Prostate · 2025
DOI: 10.1002/pros.24796 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Prostate, 2025. Verfasst von Nobumichi Tanaka und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology and Department of Prostate Brachytherapy, Nara Medical University, Kashihara, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Nitriles, Phenylthiohydantoin, Benzamides. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: The Japanese Foundation for Multidisciplinary Treatment of Cancer.
Abstract (Originalsprache)
Background
A head‐to‐head comparison between enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) revealed similar survival benefits for castration‐resistant prostate cancer (CRPC) in the ENABLE study for PCa. Considering that a dose reduction of ENZ and ABI has demonstrated sufficient inhibitory ability of androgen receptor (AR) signaling, we analyzed the efficacy of modified doses of these agents in the ENABLE study for PCa.
Methods
This investigator‐initiated, multicenter, randomized controlled trial that was conducted in Japan analyzed the prespecified survival endpoints, prostate‐specific antigen (PSA) response rate ( ≥50% decline from baseline), and safety profile in patients treated with modified doses (ENZ ≤ 120 mg/day, ABI ≤ 750 mg/day) compared with those treated with a standard dose (ENZ 160 mg/day, ABI 1000 mg/day) as a starting dose.
Results
In total, 92 patients in each arm were treated and analyzed; 16 patients were treated with a modified dose in both the ENZ and ABI arms, respectively. Moreover, 32 patients treated with modified doses showed a significantly better time to PSA progression (TTPP) and overall survival (OS) compared with the 152 patients treated with a standard dose (HR 0.47, 95%CI 0.27–0.83, p = 0.0379, and HR 0.35, 95%CI 0.19–0.63, p = 0.0162). Despite a significantly longer TTPP in the modified ABI group than in the standard ABI group (HR 0.29, 95%CI 0.14–0.62, p = 0.0248), no significant difference was observed in the TTPP between the modified and standard ENZ groups ( p = 0.5366). Furthermore, similar adverse event rates and grades were observed in each treatment dose group.
Conclusions
The modified doses of ABI showed better TTPP than the standard dose of ABI and may be a potential treatment option for CRPC patients; however, its mechanism is still unclear, although its ability to suppress AR signaling is equivalent to that of a standard dose.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology and Department of Prostate Brachytherapy, Nara Medical University, Kashihara, Japan.
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
- Department of Urology, Toyama Prefectural Central Hospital, Toyama, Japan.
- Department of Urology, Fukui-ken Saiseikai Hospital, Fukui, Japan.
- Department of Urology, Hiroshima City North Medical Center Asa Citizens Hospital, Hiroshima, Japan.
- Department of Urology, University of Yamanashi, Chuo, Japan.
ORCID-Profile: Nobumichi Tanaka, Kouji Izumi, Noriyasu Kawai, Kohei Hashimoto, Atsushi Mizokami
Förderung
- The Japanese Foundation for Multidisciplinary Treatment of Cancer
Zitieren
APA
Tanaka, N., Izumi, K., Nakai, Y., Shima, T., Kato, Y., Mita, K., Kamiyama, M., Inoue, S., Hoshi, S., Okamura, T., Yoshio, Y., Enokida, H., Chikazawa, I., Kawai, N., Hashimoto, K., Fukagai, T., Shigehara, K., Takahara, S., & Mizokami, A. (2025). Dose modification in enzalutamide and abiraterone plus prednisolone for castration‐resistant prostate cancer: A subanalysis from the ENABLE study for PCa. The Prostate. https://doi.org/10.1002/pros.24796
Vancouver
Tanaka N, Izumi K, Nakai Y, Shima T, Kato Y, Mita K, et al. Dose modification in enzalutamide and abiraterone plus prednisolone for castration‐resistant prostate cancer: A subanalysis from the ENABLE study for PCa. The Prostate. 2025. doi:10.1002/pros.24796
BibTeX
@article{Tanaka2025,
author = {Tanaka, Nobumichi and Izumi, Kouji and Nakai, Yasushi and Shima, Takashi and Kato, Yuki and Mita, Koji and Kamiyama, Manabu and Inoue, Shogo and Hoshi, Seiji and Okamura, Takehiko and Yoshio, Yuko and Enokida, Hideki and Chikazawa, Ippei and Kawai, Noriyasu and Hashimoto, Kohei and Fukagai, Takashi and Shigehara, Kazuyoshi and Takahara, Shizuko and Mizokami, Atsushi},
title = {Dose modification in enzalutamide and abiraterone plus prednisolone for castration‐resistant prostate cancer: A subanalysis from the ENABLE study for PCa},
journal = {The Prostate},
year = {2025},
doi = {10.1002/pros.24796}
}
EUVIMED